A NOVEL NUCLEAR COUNTERMEASURE TARGETING ENDOTHELIAL CELLS AND STEM CELLSTO COMBAT ARS AND DELAYED MULTIPLE ORGAN DYSFUNCTION

一种针对内皮细胞和干细胞的新型核对策，可对抗 ARS 和迟发性多器官功能障碍

• 批准号: 9915752
• 负责人: LAURIE SOWER
• 金额: $ 186.49万
• 依托单位: CHRYSALIS BIOTHERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-02-01 至 2020-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9915752
• 关键词: Acute; Animals; Biological Assay; Biological Response Modifier Therapy; Clinical Trials; Contracts; Data; Dermal; Dose; Drug Kinetics; Emergency Situation; Endothelial Cells; Excretory function; Family suidae; Functional disorder; Human; Injury; Ischemia; Licensure; Metabolism; Modeling; Mus; Musculoskeletal; Organ; Peptides; Production; Protocols documentation; Radiation; Regimen; Signal Transduction; absorption; alpha-Thrombin; animal rule; combat; irradiation; novel; nuclear countermeasure; pharmacometrics; prevent; regenerative; repaired; stem; stem cell population

Chrysalis Biotherapeutics, Inc. is pioneering the use of natural peptide regenerative signals that restore normal stem cell populations to prevent long-term damage from injury, ischemia, and radiation. In this contract they will further develop their product, TP508, a thrombin peptide by obtaining efficacy data, pathophysiological and pharmacometric data in established murine and porcine models of acute and delayed effects of acute radiation to support Animal Rule IND and licensure and initiate pivotal animal studies at the end of this project. TP508 is a repurposed product already in human clinical trials for dermal and musculoskeletal repair.

Chrysalis Biotherapeutics, Inc. 率先使用天然肽再生信号来恢复正常干细胞群，以防止损伤、缺血和辐射造成的长期损伤。在这份合同中，他们将进一步开发他们的产品 TP508，这是一种凝血酶肽，通过在已建立的急性辐射急性和延迟效应的小鼠和猪模型中获得功效数据、病理生理学和药理学数据，以支持动物规则 IND 和许可并启动关键动物研究在这个项目结束时。 TP508 是一种重新利用的产品，已进入人体临床试验，用于皮肤和肌肉骨骼修复。